Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Exelixis, Inc. (EXEL) reports that the U.S. Food and Drug Administration has extended by three months the review period for its new drug application for zanzalintinib, in combination with atezolizumab, for patients with metastatic colorectal cancer. The updated Prescription Drug User Fee Act action date is March 3, 2027.
The FDA deemed updated safety and efficacy data submitted by Exelixis to be a major amendment, which triggered the extension of the review timeline.
EXELIXIS, INC. (EXEL) reports a favorable appellate ruling in its cabozantinib patent litigation against MSN Laboratories. On August 31, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a Delaware district court judgment that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid and dismissed as moot MSN’s appeal regarding U.S. Patent No. 11,298,349, which expires on February 10, 2032.
Based on the ruling, the effective date of any final FDA approval of MSN’s ANDA for its proposed generic product may not be earlier than January 15, 2030, the expiration date of the three affirmed patents, subject to further appeals, regulatory exclusivity, and separate litigation over U.S. Patent No. 12,128,039, which expires in February 2032 and has a trial scheduled to begin in November 2026.
Farallon Capital Management, L.L.C. and affiliated individuals report beneficial ownership of 13,989,010 shares of Exelixis, Inc. common stock, representing 5.6% of the company’s outstanding shares. The ownership is reported on an amended Schedule 13D (Amendment No. 8).
The stake is held through a group of investment partnerships collectively referred to as the Farallon Funds, for which Farallon Capital Management acts as investment manager. The percentage is calculated using 247,781,692 Exelixis shares outstanding as of July 27, 2026. The approximate net investment cost for the Farallon Funds’ position is $308,124,978. Recent trading activity over the prior 60 days, all described as open-market transactions, is detailed in an exhibit referenced in the filing. The filing also formalizes a joint filing agreement among the reporting entities and individuals.
EXELIXIS, INC. director Mary C. Beckerle reported selling 9,812 shares of Common Stock on August 10, 2026 in an open-market transaction at a weighted average price of $53.66 per share, with individual trade prices ranging from $53.16 to $54.02.
After this sale, Beckerle’s reported holdings consist of 16,079 shares, all to be issued upon vesting of restricted stock units, each RSU being the economic equivalent of one share of Common Stock. The sale was executed under a Rule 10b5-1 trading plan adopted on May 8, 2026.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report their beneficial ownership in Exelixis, Inc. common stock. They disclose aggregate beneficial ownership of 11,023,943 shares of common stock, representing 4.39% of the class.
The reporting persons state shared voting power over 10,935,221 shares and shared dispositive power over 11,023,943 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the filing confirms that the Schedule 13G/A is made on behalf of both entities.
Exelixis, Inc. reported higher results for the quarter ended June 30, 2026. Total revenues rose to $628.7 million from $568.3 million a year earlier, driven mainly by CABOMETYX and other cabozantinib sales, with net product revenues of $573.0 million. Net income increased to $212.1 million, or $0.82 diluted EPS, versus $184.8 million, or $0.65. For the first half of 2026, revenues reached $1.24 billion and net income $422.5 million.
The company generated $559.6 million of operating cash flow in the first six months and ended June with $1.38 billion in cash, cash equivalents and marketable securities, after spending $753.3 million on share repurchases under its authorizations. Exelixis highlights progress for lead asset zanzalintinib, including an FDA NDA under review for metastatic colorectal cancer with a December 3, 2026 PDUFA date and multiple ongoing pivotal and phase 2 studies across tumor types. The company also describes extensive patent litigation and evolving U.S. pricing rules that could affect future CABOMETYX revenues.
Exelixis reported higher second-quarter 2026 results. Total revenues were $628.7 million, including $573.0 million of U.S. cabozantinib franchise net product revenues and $55.7 million of collaboration revenues. GAAP net income was $212.1 million, or $0.82 per diluted share, and non-GAAP net income was $237.1 million, or $0.91 per diluted share.
Full-year 2026 guidance was updated. The company now projects total revenues of $2.500–$2.550 billion and net product revenues of $2.300–$2.350 billion, with research and development expenses of $825–$875 million, selling, general and administrative expenses of $575–$625 million, cost of goods sold at 3.5%–4.5% of net product revenues, and an effective tax rate of 21%–23%.
Pipeline and capital allocation remain active. Zanzalintinib is under U.S. regulatory review for previously treated metastatic colorectal cancer, with a Prescription Drug User Fee Act target action date of December 3, 2026, and multiple phase 2 and 3 trials are ongoing or planned across several tumor types. Exelixis repurchased $311.6 million of stock in the quarter at an average price of $47.85, completing a $750 million program, and has a new authorization to repurchase up to an additional $750 million by December 31, 2027, bringing cumulative repurchases since 2023 to $2.9 billion and 93.3 million shares.
EXELIXIS, INC. director Jack L. Wyszomierski reported an open-market sale of 3,925 shares of common stock at $50.55 per share. The transaction was executed on June 1, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 284,384 shares of Exelixis common stock, and the filing notes an additional 8,367 shares that will be delivered upon vesting of restricted stock units.
EXELIXIS, INC. director Sue Gail Eckhardt reported an open-market sale of 9,812 shares of Common Stock at a weighted average price of $50.14 per share on June 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
After this transaction, her reported holdings total 16,079 shares of Common Stock, including shares that will be issued upon vesting of restricted stock units, with each unit economically equivalent to one share.